BSX Boston Scientific

8-K Current Report

Filed: February 23, 2026

Health Care

Surgical & Medical Instruments & Apparatus

Boston Scientific (BSX) 8-K current report filed with SEC EDGAR on February 23, 2026. This page provides AI-powered analysis of reported events and material disclosures, including results of operations, corporate governance changes, agreements, and other triggering events as disclosed under Form 8-K item codes.

Reported 8-K Items
3 items

Item 5.02: Departure/Election of Directors or Officers
Item 7.01: Regulation FD Disclosure
Item 8.01: Other Events

AI Filing Analysis
8-K

Item 5.02 · Departure/Election of Directors or Officers

• Board expanded from 10 to 12 directors; Catherine R. Smith and Christophe P. Weber appointed effective Feb 18, 2026
• Each new director receives prorated cash retainer ~$24,663 (vs. $125,000 annual) and equity award ~$42,420 (vs. $215,000 annual)

+3 more insights

Item 7.01 · Regulation FD Disclosure

• Reg FD filing contains only standard non-incorporation disclaimer — no material business update, guidance, or data disclosed in this excerpt

Item 8.01 · Other Events

• Board approved $4.0B increase to share repurchase authorization on Feb 18, 2026, bringing total program to $5.0B
• Full $5.0B remains available — no buybacks executed against new authorization yet

+1 more insights

Other Boston Scientific 8-K Filings

8-K Feb 26, 2026

Get deeper insights on Boston Scientific

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.